PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril
不适用
已完成
NCT04656847
| 适应症 | Coronary Artery Disease, Myocardial Infarction, Arterial Hypertension |
|---|
| 分期 | 不适用 |
|---|
| 申办方 | Servier Russia |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 504 人 |
|---|
| 干预（药物） | in daily everyday routine practice |
|---|
| 开始日期 | 2021年3月1日 |
|---|
| 完成日期 | 2021年10月5日 |
|---|
| 结果公布日 | 2024年11月1日 |
|---|
摘要
This non-interventional, ambispective study was aimed at evaluating the effectiveness, safety, and tolerability of bisoprolol and perindopril SPC in previous myocardial infarction patients with HTN and CAD treated with the drug for 12 weeks in the daily clinical practice. SPC will be used according to the approved instruction for medical use of the medicine. This is a multi-centre, observational, incomparative, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with HTN and previous MI initiated with bisoprolol/perindopril SPC in real life settings.
Antihypertensive Effectiveness (SBP and DBP) of Bisoprolol/Perindopril SPC in CAD Patients With Previous MI and HTN at Week 12 of Treatment Compared With Baseline
3 months · mm Hg
| CAD Patients With Previous MI and HTN | -24.92 ± 16.43 mm Hg |
|---|
| CAD Patients With Previous MI and HTN | -12.21 ± 11.03 mm Hg |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。